Novartis Purchases Bristol's Consumer Business
The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.
The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.